ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Crovalimab

Its studies are mostly in Hemoglobinuria, Paroxysmal · Atypical Hemolytic Uremic Syndrome · Anemia, Sickle Cell · Antiphospholipid Syndrome · Guillain-Barre Syndrome, led by Hoffmann-La Roche.

Drug pageCrovalimab: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 3, 202010 company-led studies, 5 open or runningNext primary completion: Apr 18, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche105 open or runningphase 3since Jun 3, 2020Nov 1, 2016Apr 18, 2027phase 3 · NCT04432584

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 1, 2016First study: phase 2 study in Hemoglobinuria, ParoxysmalFirst studyNCT03157635 · 59 enrolled · France, Germany, Hungary and more
  2. Jun 9, 2018Named crovalimabINNProposed as its International Nonproprietary Name in WHO's List 119
  3. Jun 3, 20202 phase 3 studies in Hemoglobinuria, ParoxysmalNCT04434092, NCT04432584
  4. Nov 30, 2020Phase 3 study in Hemoglobinuria, ParoxysmalNCT04654468 · 51 enrolled · China
  5. Apr 23, 2021Phase 3 study in Atypical Hemolytic Uremic SyndromeNCT04861259 · 83 enrolled · United States, Belgium, Brazil and more
  6. Jun 2, 2021Phase 1 study in Anemia, Sickle CellNCT04912869 · 30 enrolled · United States, Brazil, France and more
  7. Jul 6, 2021Phase 3 study in Atypical Hemolytic Uremic SyndromeNCT04958265 · 41 enrolled · United States, Belgium, Brazil and more
  8. Sep 20, 2021Phase 2 study in Anemia, Sickle CellNCT05075824 · 95 enrolled · United States, Brazil, France and more
  9. Aug 8, 2022Phase 3 study in Guillain-Barre SyndromeNCT05494619
  10. Sep 11, 2025Phase 2 study in Antiphospholipid SyndromeNCT07172022

Ahead

  1. Apr 18, 2027Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT04432584

TargetBeta

C5 →read by rule
“Complement C5 inhibitor”ChEMBL 37, by rule

Other programs on C5

ProgramCompanyFurthest phaseStudies
eculizumabruleAstraZenecaphase 438
ravulizumabruleAstraZenecaphase 435
pozelimabruleRegeneron Pharmaceuticalsphase 414
zilucoplanruleUCBphase 314
vilobelimabruleinflarx-gmbhphase 313
cemdisiranruleRegeneron Pharmaceuticalsphase 310
ABBV-6628AbbViephase 21

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07172022Antiphospholipid Syndrome2WithdrawnMar 11, 20300
NCT05494619Guillain-Barre Syndrome3WithdrawnMar 19, 20260
NCT05075824Anemia, Sickle Cell · United States, Brazil, France and more2CompletedJun 11, 202595
NCT04958265Atypical Hemolytic Uremic Syndrome · United States, Belgium, Brazil and more3Active, not recruitingJul 4, 202541
NCT04912869Anemia, Sickle Cell · United States, Brazil, France and more1CompletedDec 23, 202430
NCT04861259Atypical Hemolytic Uremic Syndrome · United States, Belgium, Brazil and more3Active, not recruitingOct 9, 202583
NCT04654468Hemoglobinuria, Paroxysmal · China3Active, not recruitingFeb 10, 202251
NCT04434092Hemoglobinuria, Paroxysmal · Argentina, Brazil, China and more3Active, not recruitingNov 16, 2022210
NCT04432584Hemoglobinuria, Paroxysmal · United States, Belgium, Brazil and more3Active, not recruitingApr 18, 2027190
NCT03157635Hemoglobinuria, Paroxysmal · France, Germany, Hungary and more2CompletedAug 13, 202659

How it is read

Names in the registry

  • “Crovalimab”, 10 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.